Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11881MR)

This product GTTS-WQ11881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3838MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ4381MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12517MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ12769MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ8972MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ13243MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ11342MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ11092MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCS-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW